3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
6
Prostatic Neoplasms
4
Neuroblastoma
4
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Glioblastoma
3
Breast Neoplasms
3
Uveal Melanoma
2
Neoplasms
2
Breast Neoplasms, Male
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Glioma
1
Ependymoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
36
Nivolumab
32
Bevacizumab
13
Sunitinib
10
Ipilimumab
10
aldesleukin
7
Interleukin-2
7
Axitinib
7
lenvatinib
6
cabozantinib
6
Paclitaxel
6
Everolimus
6
Docetaxel
6
Cyclosporine
6
Cyclophosphamide
6
fludarabine phosphate
5
Sorafenib
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
fludarabine
4
cemiplimab
4
belzutifan
4
Whole-Body Irradiation
4
Radiosurgery
4
Interferon-alpha
4
Cetuximab
4
durvalumab
3
bempegaldesleukin
3
avelumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Renal Cell
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT02429440
2017-08-17
UroRCC
University Hospital Tuebingen
Phase 1/2
Unknown
40 enrolled